A CCTA Imaging Trial to Evaluate the Effect of Obicetrapib/Ezetimibe on Coronary Plaque
A phase 3 trial registered on ClinicalTrials.gov. The registry status is active, not recruiting. It plans to enroll 300 participants.
Also called NCT06305559
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; quadruple masking; primary purpose prevention
- Phase
- Phase 3
- Enrolled
- 300 participants
- Sponsor
- Registry
-
NCT06305559
-
- Started
- (actual)
- Primary completion
- (anticipated)
- Completion
- (anticipated)
- Countries
- United States
- Registry status
- Active, not recruiting
Technical summary
Registry record NCT06305559. Randomized; quadruple masking; primary purpose prevention. Start 2024-05-16 (actual); primary completion 2027-11 (anticipated). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- A CCTA Imaging Trial to Evaluate the Effect of Obicetrapib/Ezetimibe on Coronary Plaque
- Acronym
- REMBRANDT
- Condition
- Lipidemia
- Condition
- Coronary Artery Disease
- Condition
- Plaque, Atherosclerotic
- Intervention (Drug)
- obicetrapib 10 mg + ezetimibe 10 mg FDC daily
- Intervention (Other)
- Placebo
- Lead sponsor
- NewAmsterdam Pharma
Record details
- Record id
cardio:ct-nct06305559- Content hash
6435eca96d3ab6d635836dd7bfb6fa684cd31577fc12491177404ca0e0d11bde